Search

Your search keyword '"Okada, Annabelle A."' showing total 619 results

Search Constraints

Start Over You searched for: Author "Okada, Annabelle A." Remove constraint Author: "Okada, Annabelle A."
619 results on '"Okada, Annabelle A."'

Search Results

2. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration

3. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan

4. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

5. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study

7. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic

8. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan

12. Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study

13. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study

17. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

20. TENAYA and LUCERNE

24. Incidence and Risk factors of Intraocular Inflammation after Brolucizumab Treatment in Japan: A Multicenter AMD Study

28. COVID Vaccine-Associated Uveitis

29. Posterior Uveitis

31. Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study

37. Comparative Analysis of Serum microRNA in Diagnosed Ocular Sarcoidosis versus Idiopathic Uveitis with Ocular Manifestations of Sarcoidosis

40. A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine.

44. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

46. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR

Catalog

Books, media, physical & digital resources